This information is intended for healthcare professionals based in Ireland.

Dosing in Venous Thromboembolic Events (VTE) Treatment and Prevention of Recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)

For the treatment and prevention of recurrent VTE, Only ELIQUIS® offers a short 7-day treatment initiation period and a low-dose extended therapy1*

ELIQUIS® dosing in VTE Treatment

eliquis (apixaban) dosing in vte treatment image

BD = Twice Daily
*The recommended dose of ELIQUIS® for the treatment of acute DVT and treatment of PE is 10 mg taken orally twice daily for the first 7 days followed by 5 mg taken orally twice daily.1 As per available medical guidelines, short duration of treatment (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation).1 The recommended dose of ELIQUIS® for the prevention of recurrent DVT and PE is 2.5 mg taken orally twice daily.1 When prevention of recurrent DVT and PE is indicated, the 2.5 mg twice daily dose should be initiated following completion of 6 months of treatment with ELIQUIS® 5 mg twice daily or with another anticoagulant.1

  • ELIQUIS® has a rapid onset of action,1 eliminating the need for injectable low-molecular-weight heparin therapy during initiation2
  • ELIQUIS® has no known dietary restrictions and can be taken with or without food1

ELIQUIS® dosing for treatment and prevention of DVT and/or PE

eliquis (apixaban) dosing for treatment and prevention of dvt and or pe image

Risk Minimisation Materials

The Eliquis (apixaban) Prescriber Guide and Patient Alert Card are risk minimisation materials developed for all indications as an aid to prescribing, in particular they are aimed at increasing awareness about the potential risk of bleeding during treatment with apixaban and providing guidance on how to manage that risk. Printed copies of these educational materials may be obtained by contacting the Bristol-Myers Squibb Medical Information Department (telephone: 1800 749 749; e-mail: medical.information@bms.com). Alternatively, electronic copies can be accessed via the HPRA website at http://www.hpra.ie/homepage/medicines/medicines-information/find-a-medicine.

References:

  1. ELIQUIS® (apixaban) Summary of Product Characteristics.
  2. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. New Engl J Med 2013;369:799-808.